Journal of diabetes and its complications最新文献

{"title":"Subtypes of disordered eating and their diabetes-related and psychosocial concomitants in adults with type 1 diabetes","authors":"Lilli-Sophie Priesterroth,&nbsp;Jennifer Grammes,&nbsp;Thomas Kubiak","doi":"10.1016/j.jdiacomp.2025.109067","DOIUrl":"10.1016/j.jdiacomp.2025.109067","url":null,"abstract":"<div><h3>Aims</h3><div>To identify subtypes of disordered eating behaviors (DEB) in type 1 diabetes, describing their behavioral patterns, clinical features, psychosocial well-being, and diabetes-related complications.</div></div><div><h3>Methods</h3><div>Baseline data of the Disordered Eating Behaviors and Eating Disorders in Diabetes Type I (DEBBI) study were analyzed (<em>N</em> = 645). Participants completed questionnaires assessing DEB, diabetes-related outcomes, and psychosocial well-being. Latent profile analysis identified subtypes based on DEPS-R indicators, followed by comparisons of demographic, clinical, and psychosocial variables.</div></div><div><h3>Results</h3><div>Four distinct DEB subtypes were identified, that differed in intensity and behavioral characteristics: restrained eating (moderate DEB), disinhibited eating (moderate DEB), maintaining high glucose (severe DEB), and dual compensatory behaviors (severe DEB). All DEB subtypes reported significant poorer psychosocial well-being, including elevated diabetes distress, fear of hypoglycemia, depression, and anxiety. The severe DEB subtypes showed poorer diabetes self-management and higher HbA_1c levels.</div></div><div><h3>Conclusions</h3><div>The diversity of DEB presentations in type 1 diabetes underscores the need to examine specific behavioral patterns. The subtypes revealed distinct clinical features, behavioral patterns, and variations in self-management quality, demonstrating that harmful DEB extends beyond insulin purging alone. Even moderate forms of DEB were linked to significant psychosocial burden, highlighting the importance of early detection and intervention.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109067"},"PeriodicalIF":2.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144071473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of a clinical risk score for the presence of cardiovascular autonomic neuropathy in type 1 diabetes","authors":"Pietro Pertile,&nbsp;Ilenia D'Ippolito,&nbsp;Beatrice De Santis,&nbsp;Aikaterini Andreadi,&nbsp;Davide Lauro,&nbsp;Vincenza Spallone","doi":"10.1016/j.jdiacomp.2025.109066","DOIUrl":"10.1016/j.jdiacomp.2025.109066","url":null,"abstract":"<div><h3>Aims</h3><div>To validate in an independent external population a CAN Risk Score previously developed in type 1 diabetes (T1D) and validated for cardiovascular autonomic neuropathy (CAN) with a good diagnostic accuracy.</div></div><div><h3>Methods</h3><div>Forty-seven participants with T1D (age 47.7 ± 13.2 years, duration of diabetes 30.0 (19.0–40.5) years, 24 males) underwent 4 cardiovascular reflex tests (CARTs) to diagnose early and confirmed CAN (according to 1 or 2 abnormal results). CAN Risk Score was calculated from resting heart rate, HbA1c, retinopathy and/or nephropathy, cardiovascular disease, HDL cholesterol, systolic blood pressure and smoking (range 0–10).</div></div><div><h3>Results</h3><div>Eleven participants (23.4 %) had CAN. The CAN Risk Score was higher in subjects with overall CAN (early and confirmed) (<em>P</em> = 0.0498) and with confirmed CAN (<em>P</em> = 0.0142) compared to those without, and correlated with CARTs severity (rho = 0.32, <em>P</em> = 0.026), Expiration/Inspiration ratio (<em>r</em> = −0.33, <em>P</em> = 0.0258) and Valsalva ratio (<em>r</em> = −0.47, <em>P</em> = 0.0015). A CAN Risk Score ≥ 4 was found in 19 participants and was associated with the presence of confirmed CAN (<em>P</em> = 0.0129). The CAN Risk Score showed an area under the ROC curve (AUC) of 0.802 ± 0.080 for confirmed CAN, and at the cut-off of 4, sensitivity, specificity and negative predictive values of 85.71 %, 67.50 % and 96.43 %.</div></div><div><h3>Conclusions</h3><div>This study confirmed the diagnostic value of the CAN Risk Score and supports its inclusion in a diagnostic algorithm to identify candidates for CARTs, thereby reducing universal screening. Using routinely available clinical data as categorical variables, the score is easy to calculate and implement in clinical settings.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109066"},"PeriodicalIF":2.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study","authors":"Ayman Al Hayek ,&nbsp;David C. Klonoff ,&nbsp;Wael M. Al Zahrani ,&nbsp;Suzan Eid Ibrahim ,&nbsp;Mohammed A. Al Dawish","doi":"10.1016/j.jdiacomp.2025.109064","DOIUrl":"10.1016/j.jdiacomp.2025.109064","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the long-term efficacy of a GLP-1 receptor agonist (GLP-1RA, Semaglutide) as an adjunct to insulin therapy in adults with type 1 diabetes (T1D), using continuous glucose monitoring (CGM) metrics alongside weight and metabolic outcomes.</div></div><div><h3>Methods</h3><div>In this retrospective chart review of adults with T1D on intensive insulin therapy, GLP-1RA was initiated and maintained for two years. Glycemic and metabolic parameters were evaluated at baseline, 12 months (T12), and 24 months (T24) during combination therapy.</div></div><div><h3>Results</h3><div>A total of 67 adults with T1D (56.7 % males, 43.3 % females; mean age 31.8 years, SD: 6.11; mean diabetes duration 16.6 years, SD: 5.16) were included. By 24 months, we observed improved %TIR_70–180 from 46 % to 71 % and %TIR_70–140 from 28.1 % to 47.9 % (<em>p</em> <em>&lt;</em> <em>0.001 for both</em>). GRI, including CHypo and CHyper, showed sustained reductions, and glycemic variability improved, with CV% falling from 46.3 % to 33.6 % (<em>p</em> <em>&lt;</em> <em>0.001</em>). HbA1c improved from 8.2 % to 7.1 %, with total daily insulin dose decreasing from 1.4 to 0.7 IU/kg/day (<em>p</em> <em>&lt;</em> <em>0.001</em>). Body weight and lipid profile improved, with significant reductions in weight (<em>p</em> <em>&lt;</em> <em>0.001</em>), LDL (<em>p</em> <em>&lt;</em> <em>0.001</em>), and triglycerides (<em>p</em> <em>&lt;</em> <em>0.05</em>). No hospitalizations for DKA or major adverse cardiovascular events (MACE) occurred, and short discontinuation had no significant impact on metabolic or glycemic outcomes.</div></div><div><h3>Conclusions</h3><div>The adjunctive use of GLP-1RA in T1D shows potential for improving glycemic stability and metabolic parameters without increasing hypoglycemia risk. However, further studies are needed to confirm these effects across diverse populations and over more extended periods to fully establish their long-term efficacy and safety.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109064"},"PeriodicalIF":2.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143894577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of rs490683 variant in the promoter region of the ghrelin receptor gene on body weight and metabolic syndrome after a partial meal replacement hypocaloric diet","authors":"Daniel de Luis,&nbsp;Olatz Izaola,&nbsp;David Primo,&nbsp;Daniel Rico,&nbsp;Juan Jose López","doi":"10.1016/j.jdiacomp.2025.109062","DOIUrl":"10.1016/j.jdiacomp.2025.109062","url":null,"abstract":"<div><h3>Background and aims</h3><div>Few studies have evaluated the effect of rs490683 on weight loss. The objective of our study was to evaluate the role of this variant of <em>GHSR</em> gene on body weight loss and cardiovascular risk factors secondary to a partial meal replacement (pMR) hypocaloric diet.</div></div><div><h3>Methods</h3><div>96 individuals with a body mass index (BMI &gt; 35 kg/m²) were enrolled. Participants consumed a normocaloric, hyperproteic formula twice daily (12-w). Measurements were taken for body weight, BMI, fat mass, waist circumference, blood pressure, lipid profile, fasting insulin levels and HOMA-IR.</div></div><div><h3>Results</h3><div>The genotype was 70 patients (72.9 %) CC genotype, 19 patients(19.8 %) CG genotype, and 7 patients(7.3 %) GG genotype. The intake of calories, grams of carbohydrates, fats and proteins was higher at 12w in patients carrying the G allele. BMI (−3.5 ± 0.4 kg/m² vs −1.0 ± 0.2 kg/m² (<em>p</em> = 0.01)), body weight (−8.5 ± 1.0 kg vs −2.6 ± 1.1 kg (<em>p</em> = 0.01)), fat mass (−7.7 ± 0.3 kg vs −2.6 ± 0.2 kg (<em>p</em> = 0.01)), waist circumference (−7.2 ± 0.3 cm vs −2.9 ± 0.1 cm (<em>p</em> = 0.01)), glucose levels (−12.1 ± 1.4 mg/dl vs −3.1 ± 1.8 mg/dl, <em>p</em> = 0.01), insulin (−10.8 ± 1.2 UI/L vs −3.9 ± 1.1 UI/L, <em>p</em> = 0.01), HOMA-IR (−2.1 ± 1.0 units vs −0.58 ± 0.2 units, <em>p</em> = 0.01), CRP (−1.2 ± 0.1 mg/dl vs −0.7 ± 0.2 mg/dl, <em>p</em> = 0.01), triglycerides (−22.1 ± 4.1 mg/dl vs −5.1 ± 3.2 mg/dl, <em>p</em> = 0.01), total-cholesterol (−22.2 ± 1.3 mg/dl vs −8.8 ± 1.9 mg/dl, <em>p</em> = 0.01), LDL-cholesterol (−15.2 ± 1.1 mg/dl vs −4.7 ± 1.2 mg/dl, p = 0.01), and HDL-cholesterol (6.2 ± 0.4 mg/dl vs −2.9 ± 1.2 mg/dl, p = 0.01) modifications were better in non-G allele carriers. After intervention, the odds ratio (OR) of MS in non-carrier of G allele improved OR 0.48 (95%CI: 0.31–0.73; <em>p</em> = 0.02).</div></div><div><h3>Conclusions</h3><div>G allele of rs490683 have a deleterious effect on dietary restrictions, body weight and metabolic response after a pMR diet.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109062"},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant and anti-inflammatory effects of SMTP-44D in a streptozotocin-induced diabetic neuropathy mouse model","authors":"Ryosuke Shinouchi ,&nbsp;Keita Shibata ,&nbsp;Taiju Nagatsuka ,&nbsp;Keiji Hasumi ,&nbsp;Koji Nobe","doi":"10.1016/j.jdiacomp.2025.109061","DOIUrl":"10.1016/j.jdiacomp.2025.109061","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic neuropathy (DN) is a debilitating complication of diabetes, driven by oxidative stress, inflammation, and advanced glycation end products (AGE) signaling through its receptor (RAGE). Soluble epoxide hydrolase (sEH) metabolizes anti-inflammatory epoxyeicosatrienoic acids (EETs) into pro-inflammatory dihydroxyeicosatrienoic acids (DHETs), exacerbating DN pathology. SMTP-44D, an sEH inhibitor, has demonstrated antioxidant and anti-inflammatory effects in vitro; however, its in vivo efficacy remains unclear.</div></div><div><h3>Aim</h3><div>To investigate the antioxidant and anti-inflammatory activities of SMTP-44D in relation to sEH inhibition and AGE/RAGE signaling in a streptozotocin (STZ)-induced DN mouse model.</div></div><div><h3>Methodology</h3><div>STZ-induced diabetic mice were treated with SMTP-44D (30 mg/kg) from days 8 to 28 post STZ injection (200 mg/kg). Oxidative stress markers, inflammatory factors, AGE in the sciatic nerve, and RAGE in serum were assessed via ELISA. DHET levels in serum were measured using LC-MS/MS, and apoptosis in the sciatic nerve was assessed via TUNEL staining and fluorescent immunohistochemistry for cleaved caspase-3.</div></div><div><h3>Results</h3><div>Our findings indicated that SMTP-44D inhibited sEH, reducing DHET levels and sustaining anti-inflammatory effects. It attenuated the migration of nuclear factor-kappa B, decreased AGE and RAGE levels, and suppressed oxidative stress and inflammatory markers in the sciatic nerve. Moreover, SMTP-44D inhibited apoptosis, potentially mitigating the axonal damage associated with DN.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that SMTP-44D is a promising therapeutic agent for DN, acting through sEH inhibition and reducing AGE/RAGE levels.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109061"},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143894578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of empagliflozin and dapagliflozin, SGLT2 inhibitors, on miRNA expressions in diabetes-related cardiovascular damage in rats","authors":"Humeysa Kiyak-Kirmaci ,&nbsp;Ayse Nur Hazar-Yavuz ,&nbsp;Elif Beyzanur Polat ,&nbsp;Hani Alsaadoni ,&nbsp;Ozlem Tugce Cilingir-Kaya ,&nbsp;Hanife Serife Aktas ,&nbsp;Hatice Kubra Elcioglu","doi":"10.1016/j.jdiacomp.2025.109063","DOIUrl":"10.1016/j.jdiacomp.2025.109063","url":null,"abstract":"<div><div>Type 2 diabetes mellitus (T2DM) has become a global health concern due to its rapidly increasing prevalence and associated complications. Empagliflozin and dapagliflozin, sodium-glucose co-transporter 2 (SGLT2) inhibitors, have widely used in the management of T2DM. Moreover, empagliflozin and dapagliflozin reduce the risk of cardiovascular events and associated mortality both with and also without diabetes. In the present study, it was investigated empagliflozin and dapagliflozin effects on miRNA expression in nicotinamide/streptozotocin-induced T2DM rats. The male/female rats were divided into four groups: Control, T2DM, T2DM + Empagliflozin, and T2DM + Dapagliflozin. The body weights were monitored weekly and blood pressure measurement were evaluated first and last week. IL-1β, SOD, RAGE, and cTnI levels in serum and heart tissue were detected by ELISA. The RT-PCR was used to analyze the expression levels of miRNAs in the heart tissue of diabetic rats. As a result, the most remarkable findings miR-223, miR-373, miR-22, miR-9, miR-146a, miR-21, miR-144, miR-221, and miR-34a had significantly higher expressions in the control group. Moreover, miR-146a and miR-34a levels are remarkably increased empagliflozin group comparison to the T2DM group. The miR-146a expression was increased dapagliflozin group comparison to the T2DM group. Additionally, treatments with empagliflozin and dapagliflozin showed improvements in histopathological and biochemical examinations.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109063"},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143906195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00104-7","DOIUrl":"10.1016/S1056-8727(25)00104-7","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109051"},"PeriodicalIF":2.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary factors and cancer outcomes in individuals with type 2 diabetes: A systematic review and meta-analysis of prospective observational studies","authors":"Janett Barbaresko ,&nbsp;Alexander Lang ,&nbsp;Tim Benedict Schiemann ,&nbsp;Edyta Schaefer ,&nbsp;Christina Baechle ,&nbsp;Lukas Schwingshackl ,&nbsp;Manuela Neuenschwander ,&nbsp;Sabrina Schlesinger","doi":"10.1016/j.jdiacomp.2025.109060","DOIUrl":"10.1016/j.jdiacomp.2025.109060","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer is a major health concern in persons with type 2 diabetes (T2D). Diet plays an important role in progression of diabetes and cancer. We aimed to systematically summarize the evidence on diet and cancer in individuals with T2D.</div></div><div><h3>Methods</h3><div>PubMed and Web of Science were searched until August 2023 and followed up via PubMed alert until December 2024. Prospective studies investigating any dietary factor in association with cancer in individuals with T2D were eligible.</div></div><div><h3>Results</h3><div>We identified 68 studies and conducted 20 meta-analyses. A general low-carbohydrate diet was not associated with cancer outcomes, whereas an inverse association was found for vegetable-based low-carbohydrate diet (HR per 5 points [95 % CI]: 0.90 [0.84, 0.97]; <em>n</em> = 2). We found indications of lower cancer incidence for higher adherence to Dietary Approaches to Stop Hypertension diet, (Alternate) Healthy Eating Index, higher intakes of n-3 fatty acids (0.73 [0.55, 0.98]; <em>n</em> = 2) and higher serum vitamin D (0.95 [0.93, 0.97]; <em>n</em> = 2), as well as a positive association for serum manganese concentrations (1.44 [1.11, 1.87]; n = 2), rated with low to very low certainty of evidence.</div></div><div><h3>Conclusion</h3><div>So far, the certainty of evidence is very limited due to the small numbers of primary studies. There is an indication of a possible association between diet and cancer risk among persons with T2D, but further well-designed prospective cohort studies are warranted.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109060"},"PeriodicalIF":2.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF","authors":"Tariq Jamal Siddiqi ,&nbsp;Yuxi Liu ,&nbsp;Faiez Zannad ,&nbsp;W.H. Wilson Tang ,&nbsp;Scott Solomon ,&nbsp;Julio Rosenstock ,&nbsp;Riccardo Perfetti ,&nbsp;Thomas H. Marwick ,&nbsp;Gregory D. Lewis ,&nbsp;Carolyn S.P. Lam ,&nbsp;Nasrien E. Ibrahim ,&nbsp;Justin Ezekowitz ,&nbsp;Stefano Del Prato ,&nbsp;Javed Butler ,&nbsp;James L. Januzzi","doi":"10.1016/j.jdiacomp.2025.109059","DOIUrl":"10.1016/j.jdiacomp.2025.109059","url":null,"abstract":"<div><h3>Aims</h3><div>Assess the determinants of health status and its correlation with key parameters in individuals with diabetic cardiomyopathy (DbCM).</div></div><div><h3>Methods</h3><div>In the ARISE-HF trial, the Kansas City Cardiomyopathy Questionnaire (KCCQ), cardiopulmonary exercise testing (CPET), Physical Activity Scale for the Elderly (PASE) score, echocardiographic, and laboratory assessments were performed at baseline in 691 persons with DbCM.</div></div><div><h3>Results</h3><div>Study participants with lower KCCQ-Clinical Summary Score (CSS) were predominantly women, had poorer kidney function, higher body-mass index and natriuretic peptides, and lower hemoglobin levels. Lower KCCQ-CSS scores were associated with shorter CPET duration, lower peak exercise oxygen consumption (VO₂) and lower PASE scores, but the correlations were weak (CPET duration: <em>r</em> = 0.14, 95 % CI: 0.07–0.22; peak VO₂: <em>r</em> = 0.21, 95 % CI: 0.14–0.28; PASE score: <em>r</em> = 0.19, 95 % CI: 0.11–0.26), indicating that although worse health status was linked to poorer function and activity, the strength of these relationships was limited. No meaningful associations were observed between KCCQ-CSS and echocardiographic measurements, cardiac biomarkers, or kidney function.</div></div><div><h3>Conclusion</h3><div>Health status in Stage B heart failure due to DbCM is frequently impaired. Among those with DbCM the KCCQ is only weakly correlated with the CPET parameters and PASE score implying these assessments provide unique information.</div></div><div><h3>Trial registration</h3><div>ARISE-HF, <span><span>NCT04083339</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109059"},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143890961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor by Lai-Ming Kathleen Pak et al on: Identifying predictors of SGLT2 inhibitor and GLP1R agonist use in hospital among adults with diabetes.","authors":"Michael Colacci, Ashley Raudanskis, Michael Fralick","doi":"10.1016/j.jdiacomp.2025.109046","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109046","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":" ","pages":"109046"},"PeriodicalIF":2.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}